Investor Overview

Hero Scientific: A Non-Invasive Sampling Breakthrough for Mass-Market Home Diagnostics

Our proprietary liquid concentrator replaces invasive swabs, turning painless liquid samples into lab-grade results to break the barrier to widespread adoption.

How the Concentrator Works

A 30-second, disposable device that turns a painless liquid sample into a lab-grade one.

No lab equipment required.

The Challenge

Sample collection is the single biggest challenge in home diagnostics.

Accurate results demand invasive collection: a painful urethral swab for STIs, a gag-inducing throat swab for strep. The FDA won't clear at-home tests built on methods this invasive, so the most needed tests stay locked in the clinic.

The Hero Solution

The Diagnostic Holy Grail: Lab-Grade Accuracy from a Painless Home Sample.

Frictionless Mass Adoption

Eliminating painful swabs removes the biggest barrier to both consumer adoption and at-home regulatory clearance.

Lab-Grade Precision. Instrument-Free.

We are the first technology that instantly enriches a biological fluid home sample into a highly concentrated diagnostic target. Our device replicates the processing capabilities of a clinical laboratory, completely bypassing traditional lab machinery.

Unlocking Untapped High-Value Markets

Our platform enables an entirely new class of diagnostics by transitioning testing that was previously confined to centralized laboratories. Resolving the sample collection bottleneck allows these complex, high-value tests to safely enter the mass market for the first time.

Adoption & usability

A swab-free gargle children can do - the painless sample that unlocks mass-market home testing.

Applications & Market Size

One Platform Across High-Volume, Diverse Global Industries

Current focus

Sexual Health (STIs) $3.20B TAM

2026 · Global At-Home STI Testing Market · projected to reach $5.90B by 2033 (8.9% CAGR)

Note: the decentralized, home-use subset of Fortune Business Insights' total $11.97B global STI market.

Source: Grand View Research (2026 Market Estimate)

Strep A $1.25B TAM

At-home strep testing opportunity · company estimate (bottom-up): 50% of US pharyngitis cases × at-home test price · no FDA-cleared at-home test exists today

Source: Company estimate, bottom-up TAM

Near-term R&D pipeline *

Food Pathogen Testing $6.6B TAM

2026 · Molecular (PCR / isothermal) food pathogen testing · part of the fastest-growing testing segment (~9% CAGR)

Source: MarketsandMarkets

Tuberculosis Diagnostics $2.70B TAM

2026, projected to reach $4.08B by 2034 · oral/gargle sampling is our entry angle

Source: Precedence Research

Bovine Mastitis $2.3B TAM

2026, projected to reach $4.0B by 2035 · plus $32B in annual dairy losses

Figures are 2026 total addressable market (TAM) estimates; sources noted per program.

Go to market

One Platform - Parallel Routes to Market

Our direct-to-consumer brand and B2B enterprise licensing.

Consumer flagship

A planned line of integrated, swab-free home tests distributed directly to consumers, beginning with Strep and STI diagnostics.

Target concentration validated in trials *

* In development. Integrated tests are not yet cleared or approved by the FDA.

Licensing & OEM

Licensing the concentrator to diagnostics and industry leaders who need a better sample for their existing molecular and lateral-flow platforms. Possible applications span bovine mastitis, veterinary, food safety, tuberculosis and beyond.

The consumer flagship

Swab-free, in a 3-5 second gargle.

The first and only swab-free home strep test. No driving, no waiting rooms, no throat jab.

In development. Not approved by the FDA.

A True Platform

One platform. Modular design. Endless applications.

A single, sample-agnostic device adapts across human health, animal health, and food safety, integrating seamlessly with leading diagnostic modalities—including molecular PCR and lateral flow test strips. Our current pipeline represents just our immediate R&D focus; the same core platform can power countless future applications.

Applicable across

Human health
Animal health
Food safety
Liquid biopsy

Compatible with

Lateral-flow test strips
Molecular / PCR

Deployable in

Home (OTC)
Clinic (PoC)
Collection kit for lab processing

Patent Protection

Comprehensive intellectual property coverage across the core device architecture, proprietary filtration, and sample handling mechanisms.

Patent Families

Countries Protected

U.S. Patents Issued

12-Month Strategic Roadmap

Platform Industrialization, Validation & Commercial Strategy

A synchronized path to de-risk automated manufacturing, generate multi-industry clinical evidence, and build deep commercial interest to initiate a high-value structured transaction process at Month 12.

Roadmap Fundamentals

Capital Runway

Our active $3M equity financing round is designed to fund our operational runway through pilot plastic injection mold production, small-scale manufacturing setup, and robust multi-vertical clinical data generation. Crucially, this capital enables wide engagement with the industry to generate deep awareness and commercial interest across multiple industry verticals.

Note: small-scale plastic injection molds are utilized solely for clinical and validation units; they do not represent final capital-intensive mass tooling.

Operational Transition

Hardware engineering transitions immediately from final design freeze into pilot plastic injection mold fabrication. This unlocks initial component delivery, running through November 2026 and feeding directly into small-scale production and parallel clinical trials in December 2026.

Strategic Horizon

Demonstrating our platform's versatility across multiple sectors and building early partner traction positions us to align with an investment bank at Month 12. This initiates a projected 6-12 month structured phase to capitalize on our expanding market value and execute the optimal path forward.

12-Month Operational Timeline Matrix

Strategic Tracks

Q3 2026

Jul - Sep

Q4 2026

Oct - Dec

Q1 2027

Jan - Mar

Q2 2027

Apr - Jun

Month 12+

6-12 mo

1. Finance & Strategy

$3M Financing Round
1/3 already raised

Engage Banker

2. Mfg & Production

DFM (Jul)

Plastic Injection Molds & Components (Aug - Nov)

► Small-Scale Production (Dec - Jun)

3. Clinical Validation

Strep A Clinical Trial (Starts Dec)

STI Clinical Trial (Starts Dec)

4. B2B Partnerships & Adjacent Apps

Explore Alternative Applications (Starts Oct)

B2B Industry Engagement (Starts Nov)

Corporate Strategy Manufacturing & Assembly Regulatory / Trial Data Partnerships & Applications

Detailed Strategic Breakdown

Operational Execution

Phase 1: Tooling Lock (Aug - Nov 2026): Following July's DFM, engineering commits to pilot plastic injection mold fabrication, ensuring hard-tooled components are ready and delivered by November.
Phase 2: Dual Clinical Trials (Dec - Jun): Launching in December, two separate clinical validation trials evaluate device accuracy specifically for Strep A and STIs concurrently.
Production Sync: Small-scale manufacturing runs simultaneously starting in December, utilizing parts generated from the newly validated plastic injection molds.

Partnership & Value Expansion

Platform Value Expansion: Commencing Q4 2026, we explore alternative platform applications, generating performance data across multiple diagnostic, clinical, or adjacent verticals.
Broad Industry Engagement: Initiating in November, we drive deep awareness and target business development interest across strategic channels, establishing market demand.
Establishing the Foundation: Validating our platform's versatility across multiple industries establishes the ultimate leverage to align with an investment bank at Month 12. This initiates a structured process to evaluate premium market opportunities, ensuring we capitalize on our expanding valuation from a position of strength.

* Disclaimer: R&D pipeline items and market estimates reflect target applications and projections that are not yet validated and subject to technical, regulatory, and market risks. Please read our full Investor Information & Forward-Looking Statements Disclaimer for detailed disclosures regarding our market data extrapolations and performance metrics.

Investor Access